Instem plc Stock: price and insider trades · United Kingdom
No insider purchase over the last 90 days. The latest, by Nigel Goldsmith, was filed 11 Oct 2021.
Instem plc: what insiders have been doing
Instem plc is a listed company. Filings by its managers are published through RNS (LSE). Instem plc has had no insider filing for more than a year; the last one goes back to 4 February 2022.
Over the whole record (from 2018), the tally stands at 1 purchase and 3 sales.
These figures are compiled from regulatory filings published by RNS (LSE). They describe what insiders did and are not a recommendation.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
- 40,000 shares@ £0.0275100.0% of flowIn respect of the exercise of options over Ordinary Shares: outside a trading venue In respect of the sale of Ordinary Shares: London Stock Exchange, AIM Market (XLON)ISIN GB00B3TQCK30FCA-NSM:4262624-0
- 12,500 shares@ £0.02751.7% of flowIn respect of the exercise of options over Ordinary Shares: outside a trading venue In respect of the sale of Ordinary Shares: London Stock Exchange, AIM Market (XLON)ISIN GB00B3TQCK30FCA-NSM:4262624-1
- 2,500 shares@ £8.2598.3% of flowLondon Stock Exchange, AIM Market (XLON)ISIN GB00B3TQCK30FCA-NSM:4140334Canonical exit: 9 Jan 2022 (T+90)
- 6,786 shares@ £3.4018.1% of flowLondon Stock Exchange (XLON)ISIN GB00B3TQCK30FCA-NSM:LSE20190603170651_14096836_20200326185130224_32010
- 30,000 shares@ £3.475581.9% of flowLondon Stock Exchange (XLON)ISIN GB00B3TQCK30FCA-NSM:LSE20190524170326_14087549_20200326185141318_6741
- 100,000 sharesLondon Stock Exchange (XLON)ISIN GB00B3TQCK30FCA-NSM:LSE20190219140906_13974516_20200326185109704_10936
- 140,000 sharesLondon Stock Exchange (XLON)ISIN GB00B3TQCK30FCA-NSM:LSE20180129070005_13512055_20200330111416692_4286
7 of 7 declarations
About Instem plc
Instem plc is a company specializing in IT solutions for the life sciences industry. It provides software and services for data management and drug development.
